Literature DB >> 32381294

Effects of Radiation on the Tumor Microenvironment.

Arta M Monjazeb1, Kurt A Schalper2, Franz Villarroel-Espindola2, Anthony Nguyen3, Stephen L Shiao3, Kristina Young4.   

Abstract

A malignant tumor consists of malignant cells as well as a wide array of normal host tissues including stroma, vasculature, and immune infiltrate. The interaction between cancer and these host tissues is critical as these host tissues play a variety of roles in supporting or resisting disease progression. Radiotherapy (RT) has direct effects on malignant cells, but, also, critically important effects on these other components of the tumor microenvironment (TME). Given the growing role of immune checkpoint inhibitors and other immunotherapy strategies, understanding how RT affects the TME, particularly the immune compartment, is essential to advance RT in this new era of cancer therapy. The interactions between RT and the TME are complex, affecting the innate and adaptive arms of the immune system. RT can induce both proinflammatory effects and immune suppressive effects that can either promote or impede antitumor immunity. It is likely that the initial proinflammatory effects of RT eventually lead to rebound immune-suppression as chronic inflammation sets in. The exact kinetics and nature of how RT changes the TME likely depends on timing, dose, fractionation, site irradiated, and tumor type. With increased understanding of the effects of RT on the TME, in the future it is likely that we will be able to personalize RT by varying the dose, site, and timing of intervention to generate the desired response to partner with immunotherapy strategies.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2020        PMID: 32381294      PMCID: PMC8764968          DOI: 10.1016/j.semradonc.2019.12.004

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  173 in total

Review 1.  Making sense of latent TGFbeta activation.

Authors:  Justin P Annes; John S Munger; Daniel B Rifkin
Journal:  J Cell Sci       Date:  2003-01-15       Impact factor: 5.285

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer.

Authors:  P K Chakravarty; A Alfieri; E K Thomas; V Beri; K E Tanaka; B Vikram; C Guha
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

4.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

5.  The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.

Authors:  Daniela F Quail; Robert L Bowman; Leila Akkari; Marsha L Quick; Alberto J Schuhmacher; Jason T Huse; Eric C Holland; James C Sutton; Johanna A Joyce
Journal:  Science       Date:  2016-05-20       Impact factor: 47.728

6.  Matrix crosslinking forces tumor progression by enhancing integrin signaling.

Authors:  Kandice R Levental; Hongmei Yu; Laura Kass; Johnathon N Lakins; Mikala Egeblad; Janine T Erler; Sheri F T Fong; Katalin Csiszar; Amato Giaccia; Wolfgang Weninger; Mitsuo Yamauchi; David L Gasser; Valerie M Weaver
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

7.  Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.

Authors:  Michel van Gelder; Ariane Vanclée; Catharina H M J van Elssen; Pierre Hupperets; Lotte Wieten; Gerard M Bos
Journal:  Breast Cancer Res Treat       Date:  2016-12-03       Impact factor: 4.872

8.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

9.  The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity.

Authors:  Paul M Gallo; Stefania Gallucci
Journal:  Front Immunol       Date:  2013-06-10       Impact factor: 7.561

10.  Current clinical trials testing the combination of immunotherapy with radiotherapy.

Authors:  Josephine Kang; Sandra Demaria; Silvia Formenti
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751

View more
  4 in total

Review 1.  Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?

Authors:  Sandra Demaria; Chandan Guha; Jonathan Schoenfeld; Zachary Morris; Arta Monjazeb; Andrew Sikora; Marka Crittenden; Stephen Shiao; Samir Khleif; Seema Gupta; Silvia Chiara Formenti; Bhadrasain Vikram; C Norman Coleman; Mansoor M Ahmed
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

2.  Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor.

Authors:  Åsa Kristina Öjlert; Daniel Nebdal; Igor Snapkov; Vibeke Olsen; Joel Kidman; Victor Greiff; Jonathan Chee; Åslaug Helland
Journal:  Mol Oncol       Date:  2021-09-01       Impact factor: 6.603

3.  Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide.

Authors:  Carolina de Aguiar Ferreira; Pedram Heidari; Bahar Ataeinia; Nicoleta Sinevici; Alyssa Granito; Hritik Mahajan Kumar; Eric Wehrenberg-Klee; Umar Mahmood
Journal:  Pharmaceutics       Date:  2022-07-13       Impact factor: 6.525

Review 4.  Effect of stereotactic radiotherapy on immune microenvironment of lung cancer.

Authors:  Yao Xiao; Hongqing Zhuang
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.